Optimal pandemic influenza vaccine allocation strategies for the Canadian population.
BACKGROUND
The world is currently confronting the first influenza pandemic of the 21(st) century. Influenza vaccination is an effective preventive measure, but the unique epidemiological features of swine-origin influenza A (H1N1) (pH1N1) introduce uncertainty as to the best strategy for prioritization of vaccine allocation. We sought to determine optimal prioritization of vaccine distribution among different age and risk groups within the Canadian population, to minimize influenza-attributable morbidity and mortality.


RESULTS
We developed a deterministic, age-structured compartmental model of influenza transmission, with key parameter values estimated from data collected during the initial phase of the epidemic in Ontario, Canada. We examined the effect of different vaccination strategies on attack rates, hospitalizations, intensive care unit admissions, and mortality. In all scenarios, prioritization of high-risk individuals (those with underlying chronic conditions and pregnant women), regardless of age, markedly decreased the frequency of severe outcomes. When individuals with underlying medical conditions were not prioritized and an age group-based approach was used, preferential vaccination of age groups at increased risk of severe outcomes following infection generally resulted in decreased mortality compared to targeting vaccine to age groups with higher transmission, at a cost of higher population-level attack rates. All simulations were sensitive to the timing of the epidemic peak in relation to vaccine availability, with vaccination having the greatest impact when it was implemented well in advance of the epidemic peak.


CONCLUSIONS
Our model simulations suggest that vaccine should be allocated to high-risk groups, regardless of age, followed by age groups at increased risk of severe outcomes. Vaccination may significantly reduce influenza-attributable morbidity and mortality, but the benefits are dependent on epidemic dynamics, time for program roll-out, and vaccine uptake.
Tuite
Ashleigh R
AR
Department of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Fisman
David N
DN
Kwong
Jeffrey C
JC
Greer
Amy L
AL
D017677:Age Distribution; D002138:Calibration; D002170:Canada / Q000453:epidemiology; D004196:Disease Outbreaks / Q000191:economics* / Q000517:prevention & control*; D006297:Health Services Accessibility; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000191:economics* / Q000276:immunology*; D007251:Influenza, Human / Q000453:epidemiology* / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D007362:Intensive Care Units / Q000706:statistics & numerical data; D018448:Models, Immunological; D040841:Resource Allocation / Q000191:economics*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013997:Time Factors; D016896:Treatment Outcome; D014611:Vaccination
D007252:Influenza Vaccines
Arch Intern Med. 2005 Feb 14;165(3):265-72
15710788
Euro Surveill. 2009 Oct 15;14(41):19356
19883541
JAMA. 2010 Mar 10;303(10):943-50
20215608
Influenza Other Respir Viruses. 2009 Sep;3(5):215-22
19702583
JAMA. 2010 Jan 6;303(1):37-46
20026597
Can Commun Dis Rep. 2008 Jul;34(ACS-3):1-46
18802991
PLoS Med. 2009 Dec;6(12):e1000207
19997612
Lancet Infect Dis. 2007 Oct;7(10):658-66
17897608
Euro Surveill. 2009 Jul 02;14(26):
19573509
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5692-7
17369367
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004879
16437500
MMWR Morb Mortal Wkly Rep. 2009 May 22;58(19):521-4
19478718
CMAJ. 2010 Feb 9;182(2):131-6
19959592
Vaccine. 2005 Apr 22;23(22):2851-61
15780733
N Engl J Med. 2009 Aug 13;361(7):674-9
19564633
Health Rep. 2002;13(3):9-14
12743956
N Engl J Med. 2009 Jun 18;360(25):2595-8
19423872
Biosecur Bioterror. 2009 Sep;7(3):265-73
19656012
Science. 2006 Apr 21;312(5772):447-51
16574822
N Engl J Med. 2009 Jun 18;360(25):2605-15
19423869
Vaccine. 2006 Feb 20;24(8):1159-69
16213065
Can J Public Health. 2005 Mar-Apr;96(2):145-50
15850037
Nat Immunol. 2007 Nov;8(11):1188-93
17952044
PLoS Curr. 2009 Dec 09;1:RRN1134
20033093
Science. 2009 Jun 19;324(5934):1557-61
19433588
N Engl J Med. 2006 Dec 14;355(24):2523-32
17167135
Vaccine. 2009 Apr 14;27(17):2350-5
19428850
N Engl J Med. 2009 Dec 17;361(25):2424-35
19745215
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6146-51
15071187
PLoS One. 2009 Dec 03;4(12):e8164
19997603
Nature. 2004 Dec 16;432(7019):904-6
15602562
Science. 2009 Sep 25;325(5948):1705-8
19696313
Pediatr Infect Dis J. 2007 Feb;26(2):97-106
17259870
J Infect Dis. 2008 Aug 1;198(3):305-11
18558871
Euro Surveill. 2009 Aug 13;14(32):
19679036
PLoS Med. 2008 Oct 28;5(10):e211
18959473
N Engl J Med. 2007 Oct 4;357(14):1373-81
17914038
N Engl J Med. 2009 Dec 17;361(25):2405-13
19745216
Euro Surveill. 2009 Aug 06;14(31):
19660248
N Engl J Med. 2009 Nov 12;361(20):2000-1
19907052
CMAJ. 2009 Nov 10;181(10):673-80
19825923
PLoS Med. 2008 Mar 25;5(3):e74
18366252
PLoS Med. 2006 Oct;3(10):e387
17020406